Literature DB >> 6729935

Incidence of antibody formation and positive direct antiglobulin tests in a multitransfused hemodialysis population.

L C Lasky, R R Rose, H F Polesky.   

Abstract

In order to determine the degree and significance of red cell antibody production by dialysis patients, two groups of patients were studied retrospectively. One hundred and five randomly selected dialysis patients (Group I) receiving a total of 1074 units of blood were reviewed, as were 38 patients who were given frozen-thawed red cells because of intractable nonhemolytic febrile reactions following transfusions of red cells stored conventionally (Group II). Eleven patients in Group I produced alloantibodies: nine after the start of dialysis. Of these, two patients had antibodies that were judged clinically insignificant. Eleven of 38 patients in Group II had red cell alloantibodies at the time of study, four of which were judged clinically significant. The direct antiglobulin test (DAT) was positive in 14 patients in Group I and eight patients in Group II for an overall percentage of 15. The cause of the positive DAT was determined in eluates for 26 percent of the cases studied. Clinically significant antibodies were produced by 6.7 percent of randomly selected dialysis patients (Group I). This incidence is lower than other chronically transfused patient populations reported, but higher than that reported in transfused patients at large. The incidence of positive DATs was higher than in some populations reported but not others.

Entities:  

Mesh:

Year:  1984        PMID: 6729935     DOI: 10.1046/j.1537-2995.1984.24384225020.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  Autoimmunity: a risk factor for allosensitisation to blood products?

Authors:  A S Wierzbicki; D M Cousins
Journal:  BMJ       Date:  1989-01-14

2.  Association between renal failure and red blood cell alloimmunization among newly transfused patients.

Authors:  Josine A Oud; Dorothea Evers; Rutger A Middelburg; Karen M K de Vooght; Daan van de Kerkhof; Otto Visser; Nathalie C V Péquériaux; Francisca Hudig; Johanna G van der Bom; Jaap Jan Zwaginga
Journal:  Transfusion       Date:  2020-12-09       Impact factor: 3.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.